Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 10/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 8/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 1.00 |
| ▸ | PI4KA | P42356 | 5/20 | 1.00 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 1.00 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | GAPDH | P04406 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | NADK | O95544 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798988 | 0.83 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL5506725 | 0.82 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL4054762 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL783764 | 0.81 | ADORA3 (0.68) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL8655787 | 0.81 | ADORA3 (0.68) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL4055632 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL4054756 | 0.81 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL22744253 | 0.80 | ADORA2A (0.66) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL38655924 | 0.79 | ADORA2A (0.66) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL5072517 | 0.79 | ADORA2A (0.85) | ADORA2AADORA1ADORA2BADORA3PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751159-A2 | PURINE DERIVATIVES AS A1 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2005105803-A2 | PURINE DERIVATIVES AS A1 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050245546-A1 | A1 adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-11-03 | — | — | US | claimed |
| CN-103923021-A | Heteroaryl Compounds Useful As Inhibitors Of E1 Activating Enzymes | MILLENNIUM PHARM INC | 2014-07-16 | — | — | CN | disclosed |
| CN-101516850-B | Heteroaryl compounds useful as inhibitors of E1 activating enzyme | MILLENNIUM PHARM INC | 2014-05-07 | — | — | CN | disclosed |
| CN-101516850-A | Heteroaryl compounds useful as inhibitors of E1 activating enzyme | MILLENNIUM PHARM INC (US) | 2009-08-26 | — | — | CN | disclosed |
| US-7517888-B2 | e.g. cyclopentyl(9-ethyl-8-phenylpurin-6-yl)amine; diuretic; heart failure, chronic renal disease, cirrhosis | CV THERAPEUTICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517888-B2 | e.g. cyclopentyl(9-ethyl-8-phenylpurin-6-yl)amine; diuretic; heart failure, chronic renal disease, cirrhosis | CV THERAPEUTICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517888-B2 | e.g. cyclopentyl(9-ethyl-8-phenylpurin-6-yl)amine; diuretic; heart failure, chronic renal disease, cirrhosis | CV THERAPEUTICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1751159-A2 | PURINE DERIVATIVES AS A1 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005105803-A2 | PURINE DERIVATIVES AS A1 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005105803-A2 | PURINE DERIVATIVES AS A1 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245546-A1 | A1 adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245546-A1 | A1 adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.